SAN FRANCISCO, Oct. 20, 2022 (GLOBE NEWSWIRE) — Feel Therapeutics Inc., a leader in precision digital medicine in the mental health space, announced today the recent grant of U.S. Patent No. 11,410,682, entitled Method of Detecting and Detecting an Emotional State of a user”.

The emotion detection technology developed by Feel Therapeutics is based on advanced machine learning and signal processing algorithms and methods. These algorithms analyze and identify vital signs Patterns corresponding to specific emotions to offer personalized support or therapeutic interventions. The technology passively and continuously records physiological signals through a wearable device worn by the user, as well as data from voice and other digital sources from the cell phone and Feel Therapeutics application. In order to achieve a highly accurate measurement of the user’s mood state, the wearable device features a continuous electrodermal activity (EDA) sensor developed by Feel Therapeutics.

“This patent reflects Feel’s commitment Enabling a new era of digital precision medicine in psychiatry, neuroscience and beyond. It is part of a larger portfolio of patents and intellectual property that the company has developed over the years,” said Dr. Haris Tsirmpas, Co-Founder and CTO of Feel Therapeutics. This technology addresses an urgent medical need by providing continuous, personalized and timely support to people suffering from mental disorders.”

Enabling precision digital medicine for mental health through continuous, personalized and proactive support and interventions

The benefits of real-time emotion recognition are numerous for both individuals and mental health providers. The technology offers continuous, passive and objective data monitoring about a user’s emotional state, along with context information….